Having trouble accessing articles? Reset your cache.

ETC-1002: Final Phase II data

Final data from a double-blind, U.S. Phase II trial in 60 Type II diabetics with hypercholesterolemia showed that once-daily 80 mg oral ETC-1002 for 2 weeks followed

Read the full 276 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE